February 24, 2023
Via: Contract PharmaThe U.S. FDA has approved Sanofi’s ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023